Smarter Technologies for Advancing the Next Generation of CAR-T Therapies
For immunotherapy researchers, Sartorius in vitro assay solutions reduce complexity through deeper insights, streamlined workflows via the collapse of various assays, validation of results by complementary technologies, and robust multiparametric software analysis.
The quest to extend the success of CD19 directed CAR-T therapy to other hematologic malignancies (e.g. CD123-specific ALL/AML), and ultimately solid tumors, ideally with off-the-shelf CAR-T solutions, is of paramount importance.
In order to achieve this, appropriate R&D in vitro methods are required to rapidly identify novel tumor antigens and engineer effective, tumor-seeking T-cells. This process includes evaluating various CAR delivery methods used to introduce genetic modifications as well as the continuous assessment of specificity, toxicity and activity of these modulated T-cells.
Also, for increased safety, we need to ensure through constant monitoring that, at no point in the experimental process, we allow for contamination (e.g. mycoplasma).
The iQue® advanced flow cytometry and Incucyte® automated, continuous live-cell analysis platforms (instrumentation, reagents and software solutions), in combination with rapid (< 3 hours) contamination testing and plate seeding (Picus® & Picus® NxT series) solutions form the optimal combination for your CAR-T research needs.
See Notable CAR-T Publications
NEW INFOGRAPHIC: Challenges and Solutions in CAR-T Discovery and...
Download now to learn about the challenges of developing CAR-T therapies and innovative solutions to address these challenges.
From Boutique to Global: Chimeric Antigen Receptor T-Cells as a Model for Clinical Development and Commercialization
Register now to listen to Univ. of Pennsylvania's Dr. Bruce Levine as he discusses the science of CAR T-cells and their huge global impact.
CAR T-Cell Therapy: Overcoming Toxicities
Listen to leading experts in CAR-T research, Drs. David T. Teachey and Rawan Faramand discuss novel methods to overcome toxic effects of CAR-T therapies.
CAR-T Application Highlights
Discover Our Solutions
Faster, Smarter Screening for CAR-T: iQue® Advanced Flow Cytometry Platform
A high throughput CAR-T cell analysis platform suited for T cell activation & cytokine profiling assays and multiplexed phenotypic analysis.
Speed — Fasted plate sampling, integrated analysis, multiplexed no-wash assays, and novel data reduction tools
Miniaturization — Conserve precious samples and reagents by sampling as little as a single microliter from miniaturized assay volumes
Content — High content, multiplexed analysis of cells, beads and secreted proteins
Usability — Simple, scalable, multi-user environment with walkaway automation, comprehensive analysis and visualization tools
Insight — ForeCyt Software with dynamic visualization tools provides rapid identification of wells of interest, even if run on multiple plates acquired on different days.
High throughput, multiplex screening and testing of cell-mediated cytotoxicity, targeting, and CAR transduction to get from sample to actionable results - in record time.
Validate your CAR-T Hits: Incucyte® Live-Cell Analysis System
Real-time, automated imaging and analysis of CAR-T cell homing (chemotaxis), activation and function, directly from inside your incubator.
- Real-time continuous analysis means you never miss a data point
- Profile cell-specific and time-dependent biological activity
- Visualize and validate results with images and movies
- Multiplex measurements in 96- and 384-well assay formats
Validate your HT screen results by visualizing in 2D/3D CAR-T cytotoxicity , apoptosis, and T-cell health & proliferation with integrated hardware & software solutions.
Test & Monitor for Contamination: Microsart® Detection Kits
Providing fast contaminant detection during CAR-T discovery & development for increased safety. Rapid, highly specific & sensitive.
- Detect >95% of all known bacteria in one test
- Results in 3 hours: prior to treatment
- Specific TaqMan® probes reduce false-positives
- Non-infectious validation standards
- Less pipetting: controls already included
Sensitive applications involving CAR-T cells, cancer cell lines, spheroids, require optimal external environments, that are free of contaminants. Make sure that your cells are at their physiological optimum.
Plate Seeding: Picus® and Picus® NxT Electronic Pipettes
Your pipette can be an extension of your hand, and is one of the most used (and most personal) tools in your laboratory. Manual and electronic pipette options enable multiple plate setups to optimize CAR-T cell culture and analysis conditions, while maximizing comfort and minimizing strain injuries.
Precise E:T ratios for correct % specific lysis calculations are crucial, hence minimizing the risk of error to ensure accuracy in seeding across large number is an absolute prerequisite for excellent results.
CAR-T Discovery & Development Resources
View webinars, eBooks, infographics, literature and other educational material in our CAR-T Discovery & Development Resources area.
Brochure: Smarter Technologies for Advancing the Next Generation of CAR-T Therapies | July 2020PDF | 1.2 MB
Gene-modulation Technologies in the Development of Cell-based Therapies
Cell therapy, especially adoptive T-cell transfer, is an active area of cancer research and treatment. Although promising, many challenges from efficacy to safety remain.
CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy
Register now to watch a panel of experts discuss the design, development, and success of CAR T-cell therapy and bispecific antibodies and the potential these therapeutics hold in the fight against various tumor types.